Phio Pharmaceuticals Corp.
$1.08+1.89%(+$0.02)
TickerSpark Score
50/100
100
Valuation
20
Profitability
15
Growth
84
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHIO research report →
52-Week Range8% of range
Low $0.81
Current $1.08
High $4.19
Companywww.phiopharma.com
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system.
- CEO
- Robert J. Bitterman
- IPO
- 2012
- Employees
- 5
- HQ
- Marlborough, MA, US
Price Chart
-40.98% · this period
Valuation
- Market Cap
- $12.55M
- P/E
- -1.15
- P/S
- 0.00
- P/B
- 0.76
- EV/EBITDA
- 0.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -77.34%
- ROIC
- -67.14%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-8,698,000 · -21.65%
- EPS
- $-1.45 · -59.34%
- Op Income
- $-9,220,000
- FCF YoY
- -12.34%
Performance & Tape
- 52W High
- $4.19
- 52W Low
- $0.81
- 50D MA
- $1.21
- 200D MA
- $1.51
- Beta
- 0.84
- Avg Volume
- 271.40K
Get TickerSpark's AI analysis on PHIO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 5, 26 | Lockshin Curtis | other | 16,600 |
| Feb 5, 26 | Freeman Jonathan E | other | 16,600 |
| Feb 5, 26 | Deming David H | other | 23,800 |
| Feb 5, 26 | Carson Lisa Cabott | other | 47,000 |
| Feb 5, 26 | BRADFORD PATRICIA A | other | 18,500 |
| Feb 5, 26 | Bitterman Robert J | other | 120,000 |
| Dec 31, 25 | Bitterman Robert J | buy | 5,000 |
| Dec 23, 25 | Bitterman Robert J | buy | 5,000 |
| Nov 21, 25 | Bitterman Robert J | buy | 5,000 |
| Nov 18, 25 | Bitterman Robert J | buy | 5,000 |
Our PHIO Coverage
We haven't published any research on PHIO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PHIO Report →Similar Companies
RNAZ-1.10%
TransCode Therapeutics, Inc.
$6.11
KPRX+4.76%
Kiora Pharmaceuticals, Inc.
$2.64
INAB+8.28%
IN8bio, Inc.
$1.57
BCDA-3.25%
BioCardia, Inc.
$0.92
APRE+12.49%
Aprea Therapeutics, Inc.
$0.90
MRKR+1.44%
Marker Therapeutics, Inc.
$1.41
GLTO+0.62%
Galecto, Inc.
$24.19
CELZ+3.65%
Creative Medical Technology Holdings, Inc.
$2.27